-
Member Announcements
- CDRD Partners with Université de Sherbrooke to Leverage R&D Expertise in BC and Quebec
- Celator ® Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia
- New BC Showcase launched in portal for Canadian clinical research capabilities Database will help Canada regain its position as a leading competitive nation for clinical trials
- Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis
- Celator ® Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia
- CDRD Partners with Universite de Sherbrooke to Leverage R&D Expertise in BC and Quebec
- SOHO Biotech Inc. to Participate in 2015 Medical Device Mission to Taiwan
- Austin Wang, Grade 11 Student from Vancouver, Recognized for Environmental Biotech
- DelMar Pharmaceuticals Invited to Present at The World NSCLC Summit on June 23-24, 2015
- ProNAi Therapeutics Files Registration Statement for Proposed Initial Public Offering
- STEMCELL Technologies Named Company of the Year by BIOTECanada
- Qu Biologics Appoints Jim Pankovich as Vice President, Clinical Operations and Drug Development
- JOSEPH GARCIA RECOGNIZED AS A VISIONARY LEADER IN BIOTECANADA’S 2015 GOLD LEAF AWARDS
- Vancouver Company Wins Prestigious National Award
- Mapping BC’s Path to Personalized Medicine Global experts discuss and recommend best practices for the integration of personalized medicine into healthcare
- RepliCel Life Sciences Announces Participation in 23rd World Congress of Dermatology, Vancouver, BC
- Sirona-Biochem-Corp.-2015-06-03_141817.aspx
- Xenon Pharmaceuticals To Provide Business and Milestone Update at Jefferies 2015 Global Healthcare Conference
- Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole
- Aquinox Pharmaceuticals to Present at 2015 Jefferies Global Healthcare Conference
- Charles Garcia joins StarFish Medical as new Vice President, Business Development
- Xenon Pharmaceuticals Appoints Steven Gannon to its Board of Directors
- Access to New Medicines in Public Drug Plans: Canada and Comparable Countries Report
- RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference
- Sirona-Biochem-Corp.-2015-05-20_083407.aspx
- Xenon Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update
- Aquinox Pharmaceuticals Announces First Quarter 2015 Financial Results
- Qu Biologics Granted European Patent for Use of Bacterial Compositions for the Treatment of Cancer
- ANNOUNCEMENT OF 2015 AWARD WINNERS First Annual MDDC Awards for Excellence in Biomedical Engineering
- (MSI) Completes Recruitment of Phase 2 Trial for its Novel Treatment STRADAâ„¢ for Major Depressive Disorder (MDD)
- Majority of Canadians unprepared for an allergy emergency. Team Allerject educates to save lives
- Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 KINSHIP Trial of AQX-1125 in Atopic Dermatitis
- More Federal Wage Subsidies Announced for Canadian Biotech Students
- AEQUUS AND CORIUM ENTER INTO PRODUCT DEVELOPMENT COLLABORATION FOCUSED ON CNS
- Aquinox Pharmaceuticals to Present at 2015 Bloom Burton & Co. Healthcare Investor Conference
- Qu Biologics Opens Clinical Trial Sites in Edmonton and Toronto for Crohn’s Disease Clinical Trial
- Biolux-Research-Ltd.-2015-04-23_105217.aspx
- National Access Project for Cancer Testing Gains Momentum
- SOHO Biotech Inc. to Release Histamine Elisa Kits for Testing Fish Poisoning
- RepliCel Life Sciences Receives Approval to Conduct Clinical Trial for Patients with Chronic Achilles Tendinosis
- Aquinox Pharmaceuticals to Present at 14th Annual Needham Healthcare Conference
- Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia (PHN)
- Biolux-Research-Ltd.-2015-04-01_115834.aspx
- Qu Biologics Granted U.S. Patent for Use of E. coli to Treat Crohn’s Disease
- Northview-Ventures-2015-03-27_100217.aspx
- Tekmira Presents Preclinical Results Demonstrating Super-Additive Effects on Plasma Triglyceride Lowering by Silencing of ApoC3 and ANGPTL3 Genes
- Qu Biologics Begins Research Collaboration with the University of Rochester, New York
- RepliCel Life Sciences Meets with Japanese Pharmaceutical and Medical Devices Agency (PMDA)
- SORIN GROUP SIGNS MERGER AGREEMENT WITH CYBERONICS
- Aequus-Pharmaceuticals-2015-03-17_063918.aspx
- Aequus Pharmaceuticals Lists on the TSX Venture Exchange and Appoints New Director
- XENON PHARMACEUTICALS APPOINTS DR. RICHARD H. SCHELLER TO ITS BOARD OF DIRECTORS
- Aquinox Pharmaceuticals Announces Year End 2014 Financial Results
- RepliCel Life Sciences in Japan for Key Industry Meetings
- XENON PHARMACEUTICALS REPORTS 2014 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- Response Biomedical Corp. Schedules Fourth Quarter and Fiscal Year 2014 Earnings Release and Conference Call
- Member Announcements">Aquinox Pharmaceuticals to Announce Year End 2014 Financial Results and Host Conference Call on March 16, 2015
Member Announcements
- Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2014 Financial Results and Provide Corporate Update
- Biolux-Research-Ltd.-2015-03-06_104449.aspx
- Sirona-Biochem-Corp.-2015-03-04_080855.aspx
- Qu Biologics Named Life Sciences BC Growth Stage Company of the Year
- Contextual Genomics and the Personalized Medicine Initiative Welcome Pfizer Canada to Consortium for National Access Project for Cancer Testing
- 17th Annual LifeSciences BC 2015 Award Winners, presented by FARRIS
- Patented Canadian Technology that Measures Heart Rate and Blood Oxygen Levels through Smartphones and Other Mobile Devices Approved by Health Canada
- LGTmedical Announces Issuance of U.S. Patent for Kenek Coreâ„¢ Audio Waveform Technology
- Aquinox Pharmaceuticals to Present at Cowen and Company 35th Annual Health Care Conference
- Aequus Pharmaceuticals Becomes Reporting Isuuer
- XENON PHARMACEUTICALS’ PARTNER TEVA TO INITIATE PHASE 2b CLINICAL TRIAL OF TV-45070 IN POST-HERPETIC NEURALGIA
- NSERC Brockhouse Canada Prize Honours Medical Isotope Team CycloMed99
- Response Biomedical Corp. Announces Milestone Achievement in Co-Development Collaboration
- Northern Lipids Inc is pleased to announce the appointment of Dr. Norbert Maurer as Director of R&D
- Global News – B.C. company providing free genomics cancer test to 2000 Canadians
- Contextual Genomics and the Personalized Medicine Initiative Receive Funding from AstraZeneca for National Access Project for Cancer Testing
- Notice of Upcoming Funding Opportunity 2015 Large-Scale Applied Research Project Competition Natural Resources and the Environment: Sector Challenges – Genomic Solutions
- Zymeworks Announces Bi-Specific Antibody Collaboration with Celgene
- Interprovincial collaboration launched to advance clinical research
- RepliCel Life Sciences to Present at Biotech Showcase 2015 in San Francisco
- Canadian Team Demonstrates Solution to Medical Isotope Crisis
- Pfizer Acquires Redvax GmbH
- Member Announcement
- Lilly Finalizes Novartis Animal Health Acquisition
- RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-brokered Private Placement
- Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis
- Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis
- Celator® Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia
- Industry News
- Lifescience BC Publications
-
Industry Publications
B.C. Industry News
Vancouver Sun – More than half of British Columbians say no to the flu shot
January 22, 2014
By TIFFANY CRAWFORD, VANCOUVER SUN
More than half of British Columbians have not had a flu shot this year, despite warnings from health officials that the H1N1 strain can be dangerous for some people, according to a new poll.
The Ipsos Reid survey, conducted between Jan. 13 and Jan. 17, found that 58 per cent of adults polled did not get a jab this season, with a majority of those citing the reason as they believe side effects are more problematic than catching the flu.
Most of those respondents who said no to the flu shot were under the age of 35, while the majority of those who had one were over 55.
Also, those who have not been inoculated are not intending to this season. The poll found only five per cent of British Columbians without the shot say that they “definitely will†or “probably will†get the flu shot this season.
The poll suggests that a strong majority think convenience is an non-issue, and agree that “it is easy and convenient to get a flu shot for those who want one.â€
However, Vancouver Sun columnist Stephen Hume earlier this month reported on the efforts of two people in their 20s who experienced frustrations and delays in acquiring this year’s vaccine, finding that many pharmacies were out of stock.
Provincial Health Officer Dr. Perry Kendall said earlier this month that the province distributed about 1.3 million doses of flu vaccine for the current season.
Perry said B.C. is usually near the top of the list among provincial vaccination rates, with about 30 per cent of the total population normally getting a flu shot. He said 90,000 doses – worth a total of about $500,000 – were returned unused last year.
Residents are split on whether there may be side effects of the flu shot that cause more problems than getting sick, the poll shows. Overall, 43 per cent agree and 41 per cent disagree that the side effects might be worse.
Ipsos Reid says there are slightly more residents who agree (43 per cent) than disagree (39 per cent) that the H1N1 influenza has been sensationalized.
The poll has a margin of error plus or minus 3.9 percentage points had all British Columbia adults been surveyed.
© Copyright (c) The Vancouver Sun